Geron Corp splits its revenue into 7 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Revenues Before Adjustments at $74.5 million, 124% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
60
|
57
|
52
|
—
|
47
|
49
|
40
|
—
|
| Revenues Before Adjustments |
—
|
74
+23.8%
share 123.8%
|
72
+25.2%
share 126.0%
|
65
+44.2%
share 126.1%
|
60
+6.9%
|
60
share 127.4%
|
58
share 118.0%
|
45
share 114.4%
|
56
|
| Royalty |
—
|
0
+26.7%
share 0.1%
|
0
-75.9%
share 0.0%
|
0
-60.5%
share 0.1%
|
0
-93.5%
|
0
share 0.1%
|
0
share 0.1%
|
0
share 0.4%
|
0
|
| Government Rebates |
—
|
-2
-5.6%
share -3.8%
|
-2
-329.0%
share -3.4%
|
-2
-2412.1%
share -3.2%
|
0
+111.8%
|
-2
share -4.5%
|
-0
share -0.9%
|
-0
share -0.2%
|
-1
|
| Distributor Service Fees |
—
|
-2
share -4.1%
|
-2
-21.6%
share -4.1%
|
-2
-42.1%
share -4.2%
|
-2
|
—
|
-2
share -4.0%
|
-2
share -3.9%
|
—
|
| Chargebacks And Customer Credits |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-8
|
| Chargebacks |
—
|
-10
-37.3%
share -16.1%
|
-9
-54.7%
share -16.0%
|
-8
-95.7%
share -15.7%
|
-8
|
-7
share -14.9%
|
-6
share -12.1%
|
-4
share -10.5%
|
—
|
| Total Gross To Net Adjustments |
—
|
—
|
-15
-68.7%
share -26.0%
|
-14
share -26.2%
|
-12
-40.2%
|
-13
share -27.6%
|
-9
share -18.1%
|
—
|
-8
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GERN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 886744
- Former names
- GERON CORPORATION (until Aug 5, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.